Literature DB >> 23777266

Magnesium intake and risk of amyotrophic lateral sclerosis: results from five large cohort studies.

Elinor Fondell1, Eilis J O'Reilly, Kathryn C Fitzgerald, Guido J Falcone, Marjorie L McCullough, Yikyung Park, Laurence N Kolonel, Alberto Ascherio.   

Abstract

A low magnesium intake has been suggested to be associated with amyotrophic lateral sclerosis (ALS) in pathological and case-control studies, but prospective studies in humans are lacking. The relation between dietary intake of magnesium and ALS risk was explored in five large prospective cohort studies (the Nurses' Health Study, the Health Professionals Follow-up Study, the Cancer Prevention Study II Nutrition Cohort, the Multiethnic Cohort Study, and the National Institutes of Health - AARP Diet and Health Study), comprising over 1,050,000 males and females contributing 1093 cases of ALS during a mean of 15 years of follow-up. Cox proportional hazards models were used within each cohort, and cohort-specific estimates were subsequently pooled using a random-effects model. Results demonstrated that dietary magnesium intake was not associated with ALS risk, relative risk 1.07, 95% confidence interval 0.88 - 1.31 comparing the highest quintile of intake with the lowest. This finding does not support a protective effect of magnesium intake on ALS risk. Further analyses should explore magnesium intake in combination with heavy metal exposure and genetic variants affecting magnesium absorption.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23777266      PMCID: PMC3743429          DOI: 10.3109/21678421.2013.803577

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Frontotemporal Degener        ISSN: 2167-8421            Impact factor:   4.092


  34 in total

1.  Validation of the American Cancer Society Cancer Prevention Study II Nutrition Survey Cohort Food Frequency Questionnaire.

Authors:  E W Flagg; R J Coates; E E Calle; N Potischman; M J Thun
Journal:  Epidemiology       Date:  2000-07       Impact factor: 4.822

2.  Risk factors in the early diagnosis of ALS: European epidemiological studies.

Authors:  A Chiò
Journal:  Amyotroph Lateral Scler Other Motor Neuron Disord       Date:  2000-03

Review 3.  ER chaperone-metal interactions: links to protein folding disorders.

Authors:  Evelyn Tiffany-Castiglioni; Yongchang Qian
Journal:  Neurotoxicology       Date:  2012-02-20       Impact factor: 4.294

4.  Prognosis in amyotrophic lateral sclerosis: a population-based study.

Authors:  M A del Aguila; W T Longstreth; V McGuire; T D Koepsell; G van Belle
Journal:  Neurology       Date:  2003-03-11       Impact factor: 9.910

5.  Design and serendipity in establishing a large cohort with wide dietary intake distributions : the National Institutes of Health-American Association of Retired Persons Diet and Health Study.

Authors:  A Schatzkin; A F Subar; F E Thompson; L C Harlan; J Tangrea; A R Hollenbeck; P E Hurwitz; L Coyle; N Schussler; D S Michaud; L S Freedman; C C Brown; D Midthune; V Kipnis
Journal:  Am J Epidemiol       Date:  2001-12-15       Impact factor: 4.897

6.  Disease progression in amyotrophic lateral sclerosis: predictors of survival.

Authors:  T Magnus; M Beck; R Giess; I Puls; M Naumann; K V Toyka
Journal:  Muscle Nerve       Date:  2002-05       Impact factor: 3.217

7.  The American Cancer Society Cancer Prevention Study II Nutrition Cohort: rationale, study design, and baseline characteristics.

Authors:  Eugenia E Calle; Carmen Rodriguez; Eric J Jacobs; M Lyn Almon; Ann Chao; Marjorie L McCullough; Heather S Feigelson; Michael J Thun
Journal:  Cancer       Date:  2002-05-01       Impact factor: 6.860

8.  A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics.

Authors:  L N Kolonel; B E Henderson; J H Hankin; A M Nomura; L R Wilkens; M C Pike; D O Stram; K R Monroe; M E Earle; F S Nagamine
Journal:  Am J Epidemiol       Date:  2000-02-15       Impact factor: 4.897

Review 9.  An evidence-based medicine approach to the evaluation of the role of exogenous risk factors in sporadic amyotrophic lateral sclerosis.

Authors:  Carmel Armon
Journal:  Neuroepidemiology       Date:  2003 Jul-Aug       Impact factor: 3.282

10.  Amyotrophic lateral sclerosis in Olmsted County, Minnesota, 1925 to 1998.

Authors:  Eric J Sorenson; Andrew P Stalker; Leonard T Kurland; Anthony J Windebank
Journal:  Neurology       Date:  2002-07-23       Impact factor: 9.910

View more
  5 in total

1.  Intakes of caffeine, coffee and tea and risk of amyotrophic lateral sclerosis: Results from five cohort studies.

Authors:  Elinor Fondell; É Ilis J O'Reilly; Kathryn C Fitzgerald; Guido J Falcone; Laurence N Kolonel; Yikyung Park; Susan M Gapstur; Alberto Ascherio
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2015-03-30       Impact factor: 4.092

2.  Association Between Dietary Intake and Function in Amyotrophic Lateral Sclerosis.

Authors:  Jeri W Nieves; Chris Gennings; Pam Factor-Litvak; Jonathan Hupf; Jessica Singleton; Valerie Sharf; Björn Oskarsson; J Americo M Fernandes Filho; Eric J Sorenson; Emanuele D'Amico; Ray Goetz; Hiroshi Mitsumoto
Journal:  JAMA Neurol       Date:  2016-12-01       Impact factor: 18.302

Review 3.  Exploring targets and therapies for amyotrophic lateral sclerosis: current insights into dietary interventions.

Authors:  Shyuan T Ngo; Jia D Mi; Robert D Henderson; Pamela A McCombe; Frederik J Steyn
Journal:  Degener Neurol Neuromuscul Dis       Date:  2017-07-25

4.  "Calcium bombs" as harbingers of synaptic pathology and their mitigation by magnesium at murine neuromuscular junctions.

Authors:  Kosala N Dissanayake; Robert R Redman; Harry Mackenzie; Michael Eddleston; Richard R Ribchester
Journal:  Front Mol Neurosci       Date:  2022-07-26       Impact factor: 6.261

Review 5.  Metabolic Abnormalities, Dietary Risk Factors and Nutritional Management in Amyotrophic Lateral Sclerosis.

Authors:  Emanuele D'Amico; Giuseppe Grosso; Jeri W Nieves; Aurora Zanghì; Pam Factor-Litvak; Hiroshi Mitsumoto
Journal:  Nutrients       Date:  2021-06-30       Impact factor: 5.717

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.